These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 30150078)

  • 21. Thrombocytopenia in pediatric patients on concurrent cannabidiol and valproic acid.
    McNamara NA; Dang LT; Sturza J; Ziobro JM; Fedak Romanowski EM; Smith GC; Joshi SM; Leber SM; Carlson M; Robertson P; Shellhaas RA
    Epilepsia; 2020 Aug; 61(8):e85-e89. PubMed ID: 32614070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world evidence on the use of cannabidiol for the treatment of drug resistant epilepsy not related to Lennox-Gastaut syndrome, Dravet syndrome or Tuberous Sclerosis Complex.
    Espinosa-Jovel C; Riveros S; Bolaños-Almeida C; Salazar MR; Inga LC; Guío L
    Seizure; 2023 Nov; 112():72-76. PubMed ID: 37769547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cannabinoid therapy in epilepsy.
    Billakota S; Devinsky O; Marsh E
    Curr Opin Neurol; 2019 Apr; 32(2):220-226. PubMed ID: 30676535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cannabidiol in the Treatment of Epilepsy.
    von Wrede R; Helmstaedter C; Surges R
    Clin Drug Investig; 2021 Mar; 41(3):211-220. PubMed ID: 33559102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The proposed mechanisms of action of CBD in epilepsy.
    Gray RA; Whalley BJ
    Epileptic Disord; 2020 Jan; 22(S1):10-15. PubMed ID: 32053110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of cannabinoids in epilepsy treatment: a critical review of efficacy results from clinical trials.
    Nabbout R; Thiele EA
    Epileptic Disord; 2020 Jan; 22(S1):23-28. PubMed ID: 31916540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Purified Cannabidiol for Treatment of Refractory Epilepsies in Pediatric Patients with Developmental and Epileptic Encephalopathy.
    Pietrafusa N; Ferretti A; Trivisano M; de Palma L; Calabrese C; Carfì Pavia G; Tondo I; Cappelletti S; Vigevano F; Specchio N
    Paediatr Drugs; 2019 Aug; 21(4):283-290. PubMed ID: 31179531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.
    Chen JW; Borgelt LM; Blackmer AB
    Ann Pharmacother; 2019 Jun; 53(6):603-611. PubMed ID: 30616356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Utility of Cannabidiol in the Treatment of Refractory Epilepsy.
    Reddy DS
    Clin Pharmacol Ther; 2017 Feb; 101(2):182-184. PubMed ID: 27506704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cannabidiol Treatment for Refractory Seizures in Sturge-Weber Syndrome.
    Kaplan EH; Offermann EA; Sievers JW; Comi AM
    Pediatr Neurol; 2017 Jun; 71():18-23.e2. PubMed ID: 28454984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cannabinoids in treatment-resistant epilepsy: A review.
    O'Connell BK; Gloss D; Devinsky O
    Epilepsy Behav; 2017 May; 70(Pt B):341-348. PubMed ID: 28188044
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex.
    Hess EJ; Moody KA; Geffrey AL; Pollack SF; Skirvin LA; Bruno PL; Paolini JL; Thiele EA
    Epilepsia; 2016 Oct; 57(10):1617-1624. PubMed ID: 27696387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: Systematic review and meta-analysis.
    de Carvalho Reis R; Almeida KJ; da Silva Lopes L; de Melo Mendes CM; Bor-Seng-Shu E
    Epilepsy Behav; 2020 Jan; 102():106635. PubMed ID: 31731110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy.
    Press CA; Knupp KG; Chapman KE
    Epilepsy Behav; 2015 Apr; 45():49-52. PubMed ID: 25845492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isobolographic analysis of adjunct antiseizure activity of the FDA-approved cannabidiol with neurosteroids and benzodiazepines in adult refractory focal onset epilepsy.
    Golub V; Ramakrishnan S; Reddy DS
    Exp Neurol; 2023 Feb; 360():114294. PubMed ID: 36493860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacology and drug interactions of cannabinoids.
    Landmark CJ; Brandl U
    Epileptic Disord; 2020 Jan; 22(S1):16-22. PubMed ID: 31941642
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cannabis for paediatric epilepsy: challenges and conundrums.
    Chen KA; Farrar MA; Cardamone M; Lawson JA
    Med J Aust; 2018 Feb; 208(3):132-136. PubMed ID: 29438649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of cannabis for treating children with refractory epilepsy.
    Neale M
    Nurs Child Young People; 2017 Sep; 29(7):32-37. PubMed ID: 29115760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials.
    Silvestro S; Mammana S; Cavalli E; Bramanti P; Mazzon E
    Molecules; 2019 Apr; 24(8):. PubMed ID: 31013866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.
    Porter BE; Jacobson C
    Epilepsy Behav; 2013 Dec; 29(3):574-7. PubMed ID: 24237632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.